고려대학교

초록/요약

Myocardial infarction leads to loss of tissue and impairment of cardiac performance. Because cardiomyocytes have alimited ability to self-renewal, and thus the transplantation of adult stem cells into infarcted region is a promisingtherapy to regenerate damaged cardiac tissue. Stem cells for myocardial regeneration are mesenchymal- andhematopoietic stem cells derived from bone marrow, or skeletal myoblasts in animals, and these stem cells generatedcardiomyocytes and endothelial cells in the infarcted regions, and improved cardiac function. Clinical data showed thatautologous mesenchymal stem cells and skeletal myoblasts increased ejection fraction and blood flow, and decreasedinfarct size in patients. Some researchers have used a different strategy that cytokine-mobilized bone marrow cells orangioblasts homed to the infarcted region, replicated, differentiated, and improved cardiac function. The current trend isthe combined use of cytokine treatment and cell transplantation to increase the efficiency of myocardial regeneration. Inaddition, genetic manipulation of adult stem cells has been done to express cardioprotective recombinant proteins, orenhance angiogenesis in animal study. Thus cellular transplantation, cytokine induction and gene therapy should not beviewed as competitive but rather as complementary with the common and final goal of improving the outcome of heartfailure patients. In this review, we will discuss about studies for myocardial repair in animal and in patients.